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Abstract
In 2003 the Motor Neurone Disease (MND) Association, together with The Wellcome Trust, funded the creation of a
national DNA Bank specific for MND. It was anticipated that the DNA Bank would constitute an important resource
to researchers worldwide and significantly increase activity in MND genetic research. The DNA Bank houses over
3000 high quality DNA samples, all of which were donated by people living with MND, family members and
non-related controls, accompanied by clinical phenotype data about the patients. Today the primary focus of the
UK MND DNA Bank still remains to identify causative and disease modifying factors for this devastating disease.
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Motor Neuron Disease (MND) is a fatal, rapidly pro-
gressive disease that affects the brain and spinal cord
and which ultimately leads to respiratory failure around
2–5 years following symptom onset [1, 2]. Approximately
1 in 300 people develop MND but its prevalence is low,
at about 6–8 in 100,000 because of short life expectancy
[3]. There is no diagnostic test and treatment is largely
palliative, with only one agent, riluzole, having a modest
effect in extending survival. Genetic factors undoubtedly
play a role in most cases of the disease, both in patho-
genesis and rate of progression, with about 5–10 % of
all patients having a clear family history of MND and
in some cases, frontotemporal dementia [4–6]. Over
100 genes have now been implicated in the causation
of MND [7]. No consistent environmental risk factor
has been identified, although it is possible that such
factors may trigger disease in genetically susceptible
individuals, and therefore it is plausible that apparent
sporadic cases of MND will be genetically determined
to some degree [8, 9].
An essential starting point for successful genetic re-
search is access to high quality samples, accompanied
by detailed clinical information. Large-scale gene sequen-
cing and association studies need many thousands of
samples to be screened such that results are statistically
significant. Access to such samples had become a major
obstacle in exploring the pathogenesis of MND and the
concept of an MND DNA Bank was born. The objectives
of the initial study were threefold: 1) To collect cohorts
of patient, parent/sibling and control samples from spor-
adic and familial MND; 2) To collect clinical information
in order to examine susceptibility traits in clinical sub-
groups of MND; 3) To make this resource available
to the international research community and to foster
collaboration between research teams, in order to iden-
tify genetic risk factors for MND.
Organisational structure of the UK MND DNA
Bank
The UK MND DNA Bank was a collaborative project
adopting a ‘Hub and Spoke’ model, with three regional
‘Hub’ centres linking with a total of 16 ‘Spoke’ centres
across England, Wales, Scotland and Northern Ireland
(Table 1). Recruitment to the study and sample collec-
tion was coordinated at the Hub centres by a DNA Bank
Co-odinator based in London. Samples were obtained
from sporadic and familial MND patients attending
MND clinics in the UK, their spouses (or other gene-
tically unrelated controls) and blood relatives by hub
centre-based nurses. A DNA Bank research nurse was
affiliated to each Hub centre to act as patient liaison,
collect clinical information from patients, controls and
family members, and take blood samples. Samples within
the UK MND DNA Bank are housed at CIGMR Biobank,
at the University of Manchester. In addition, as one of
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the Public Health England collections, the European
Collection of Cell Cultures (ECACC) manages the trans-
formation and storage of EBV-transformed lymphocytes
derived from blood samples from participants providing
an everlasting supply of DNA for the Bank.
The UK MND DNA Bank was a collaborative pro-
ject adopting a ‘hub and spoke’ model. Three regional
Hub Centres were established at London (King’s Col-
lege Hospital), Sheffield (Royal Hallamshire Hospital),
and Birmingham (Queen Elizabeth Hospital) linking with
a total of 16 ‘spoke centres’ spread across England,
Scotland, Wales and Northern Ireland. These included
hospitals that are part of the MND Association’s Care
Centre Network and centres, which form part of the
Department of Health/NIHR Dementias and Neurode-
generative Diseases Research Network (DeNDRoN).
The MND Association’s Biomedical Research Advisory
Panel (BRAP) oversee the governance and the strategic
development of the DNA Bank, ensuring that samples
are utilised in an appropriate fashion, and that any
clinical information requested is appropriate for the
proposed study. Applications for sample use are only
considered for projects which have guaranteed funding
and as a result, have been peer reviewed. In addition, the
Technical Access Committee (TAC) at CIGMR Biobank,
determine sample requirements for the technology
platform to be used, the quantity of sample required
and ensure any leftover samples are returned or destroyed.
All applications for access to the samples are judged on
merit. Having obtained approval from BRAP and the
technical access committee, applicants select samples
from the DNA Bank in collaboration with the MND
Association based on their requirements for specific
patient cohorts e.g. gender, site of onset etc. This en-
sures that all the required parameters of the project
are met, whilst maintaining strict governance over which
samples are used. In order to receive material and clinical
information from the DNA Bank, all applicants must
agree to the terms and conditions of sample use (see
Additional file 1). This specifies the user and specific
purpose for which the samples and data are to be li-
censed, including standard terms as to the ownership,
exploitation and dissemination of results, and require-
ments that the user conforms to the terms of the par-
ticipants’ consent.
Sample collection, storage and quality control
Sample collection began in 2003. All participants were
over 18 years of age. In order to ensure that the patient
cohort was representative of disease prognosis, patients
must have experienced symptom onset (significant muscle
weakness) on or after January 2002. All patients fulfilled
El Escorial criteria for probable or definite Amyotrophic
Lateral Sclerosis (ALS) [10]. Patients presenting with
Progressive Muscular Atrophy (PMA), Primary Lateral
Sclerosis (PLS) or Progressive Bulbar Palsy (PBP) [11, 12]
were also included in the study. Patients were recruited
by consultant neurologists with a specialist interest in
MND in participating centres. Patients participating in
other clinical research projects were not excluded from
the study. Blood samples were also collected from con-
senting partners/carers, providing some degree of match-
ing in terms of age, education, environmental exposure
and often ethnicity. Where patients presented with fa-
milial MND, blood samples were collected from family
members for linkage analysis. Where patients presented
with sporadic MND, where possible, blood samples were
also collected from parents or from a parent and sibling,
to give so-called ‘Trio Samples’ increasing the amount of
genetic information available for researchers.
Informed consent to participate was sought from all
patients, family members and controls. Ethical approval
for the collection of samples and the creation of the
UK MND DNA Bank was given by the Trent Research
Ethics Committee in February 2003 ref MREC/02/4/107
and in July 2009, ref 09/HO405/32. Participants were
provided with detailed information and contact details
and could withdraw from the study at any time. The
samples were pseudo-anonymised and an online bespoke
clinical database was developed to facilitate data entry
and collection by the research nurses and enable track-
ing of trends in clinical parameters such as symptom
onset and presentation for data analysis. Storage and
Table 1 Hub and spoke model for sample collection
King’s College Hospital, London Queen Elizabeth Hospital, Birmingham Royal Hallamshire Hospital, Sheffield
The National Hospital for Neurology and Neurosurgery,
and Royal Free Hospital, London
John Radcliffe Hospital, Oxford Royal Preston Hospital
Bart’s and The London NHS Trust Belfast City Hospital Greater Manchester Medical Centre, Manchester
Poole NHS Trust Walton Neurological Centre, Liverpool Ninewells Hospital, Dundee
Cambridge University Hospital Southmead Hospital, Bristol Queen’s Medical Centre, Nottingham
Derriford Hospital, Plymouth Royal Victoria Infirmary, Newcastle
Southampton University Hospital
Queen’s Hospital, Romford
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access to this data set is in accordance with the UK Data
Protection Act 1998 [13]. As custodians of the DNA
Bank all enquiries for access to the clinical data or about
the database itself must be directed through the MND
Association.
Prior to 2010, DNA extraction from donated blood
samples was carried out at individual Hub centres using
the Nucleon BACC3 protocol (Amersham, UK). Ex-
tracted DNA was sent to CIGMR Biobank for long-term
storage. On receipt, all DNA samples were run on 1 %
agarose gels alongside molecular weight markers of
appropriate size to check integrity. From August 2010,
DNA extraction was carried out at CIGMR Biobank
using automated robotic processing under ISO900:2000
operating standards. In all cases, both when imported
from Hub centres, or extracted by CIGMR Biobank
themselves, DNA concentration was measured using a
nanodrop spectrophotometer. Samples with OD ratios
outside the normal range were removed from the cohort
and contaminants washed using ethanol precipitation.
Final DNA concentration was measured using Quant-iT™
Picogreen® dsDNA Assay Kit (Invitrogenc™ Life Tech-
nologies, UK). Samples were measured on 96 well plates,
in triplicate against standards of known concentration
for quality control.
DNA aliquots are stored in 2D bar coded tubes for
sample tracking purposes. A relational database recorded
the 2D barcodes associated with each patient/donor
ID. All samples within the collection were screened
for gender using PCR on presumed duplicate samples
according to standard protocols. Samples with a mis-
match between the expected gender as recorded in the
patient information, and actual gender as confirmed
by PCR, were rescreened using an alternative PCR
method of gender identification based on the absence/
presence of Alu sequence [14]. Any samples with a
confirmed discrepancy were ring fenced from the col-
lection and suspended from the in-house laboratory
management system.
Peripheral blood lymphocytes (PBLs) were isolated
from whole blood samples at ECACC using density gra-
dient centrifugation. An aliquot of untransformed PBLs
was stored in liquid nitrogen for safekeeping, whilst the
remaining PBLs were transformed using the Epstein Barr
virus according to standard protocols [15]. As part of
routine quality assurance, all cell lines were screened for
Mycoplasma contamination, and a proportion of every
batch tested for sterility, cell count and viability. Authen-
ticity against source material (blood spot card prepared
at receipt) using STR-PCR profiling confirmed that no
sample mix ups had occurred during processing. The
resulting lymphoblastoid cell lines were cryopreserved
and are used to restock the DNA Bank when stock levels
become low.
The UK MND DNA Bank
In October 2012, at the end of the collection period,
the UK MND DNA Bank comprised 3159 high quality
DNA samples. Of these, 1344 samples were taken
from individuals diagnosed with sporadic MND (see
Fig. 1a and 1b). There were 133 familial MND samples
within the collection and a further 500 samples taken
from family members, including samples that form 28
parent trio sets and 27 sibling trio sets. The remaining
1085 samples were taken from controls. In line with
population-based demographic for the disease [16] the
breakdown of gender in the collection is around 60 %
male (Fig. 1a). The average age of onset was approxi-
mately 62 years of age (Fig. 1c). Each sample is ac-
companied by a minimum dataset of: age at which the
samples were taken; gender; disease status; and where
appropriate diagnostic certainty (El Escorial Status) and
age of onset (calculated from date of birth and date of
symptom onset). An extended dataset has been collected
for as many participants as possible (see Fig. 2) but it
is not a complete dataset for the entire collection.
Data varies greatly for each characteristic, for example,
data such as site of onset and dominant hand has
been taken for around 97 % of all patient participants,
whilst Riluzole usage has only been noted for around
85 % of all patient participants. In total 2653 frozen
lymphoblastoid cell lines are held in storage at ECACC
following a PBL transformation success rate of 97 %.
Of these, 1267 samples were generated from whole
blood taken from patients with sporadic MND. 115
cell lines were generated from familial samples and the
remaining 1058 cells lines have been established using
blood samples obtained from control or family mem-
bers (see Fig. 1d). Researchers are able to access trans-
formed cell lines in collaboration with the Principal
Investigators of the DNA Bank for use in genomic re-
search projects approved by BRAP.
Each sample withdrawn from the UK MND DNA
Bank is accompanied by a minimum dataset of: age at
which the samples were taken; gender; disease status;
and where appropriate diagnostic certainty (El Escorial
Status) and age of onset (calculated from date of birth
and date of symptom onset). An extended dataset has
been collected for as many participants as possible but
it is not a complete dataset for the entire collection.
The clinical information was collected by the Research
Nurse using a brief clinical questionnaire. Identifying
data was kept at each Hub centre in secure locations
in accordance with the Data Protection Act.
Table 2 shows the success rates for PCRs performed
on the DNA samples within the collection. The failure
rate of the quality control assay was less than 1.5 %,
suggesting that the quality of DNA within the collection
is very high. The gender results from these assays were
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directly compared to the gender recorded for individuals
on the clinical database. Where there was a discrepancy
between the expected gender and that determined in
the assay, patient clinical notes were rechecked. In the
absence of a clerical error, samples were rescreened
using both the original AMEL marker and an alterna-
tive gender marker, the Human ALU expansion [14].
In total, 3,415 individual samples were screened to
confirm gender.Sixty two samples that continued to
show a discrepancy between the expected gender and
the assay gender were ring fenced from the collection
and suspended from the laboratory management
system.
Quality control assays were carried out across the
collection. Sixty two samples showed a continued dis-
crepancy between the gender of the actual DNA sample
and that stated in the clinical notes and were ring fenced
from the collection.
The UK MND DNA Bank was designed to be an
international research resource with the fundamental
guarantee that it would supply high quality DNA samples
with good integrity and accompanying high quality clin-
ical data. Establishing the resource was challenging and
understandably the DNA Bank does have limitations.
DNA samples from the bank represent an incident not
prevalent population and are unlikely to be biased
however, the genomic DNA supply itself is limited and
although cell lines have been established, the DNA from
such cell lines may have sequence changes compared
with the original genomic samples and be unsuitable for
use in some applications [17, 18]. This fact must be
considered when choosing to use cell line derived DNA
even if the DNA itself is of a high standard as demon-
strated by the rigorous quality control assays in place. In
addition, genomic DNA taken from the blood may not be
entirely representative of the disease. It is possible that
causative gene mutations for sporadic MND are somatic
and as a result are found only in the cells of the central
nervous system that are affected by disease and would
therefore not be present in the blood samples provided
A B
C D
Fig. 1 The UK MND DNA Bank. The UK MND DNA Bank comprises 3159 high quality DNA samples. 1344 samples were taken from individuals
diagnosed with sporadic MND (a and b). There were 133 familial MND samples within the collection and a further 500 samples taken from family
members, including samples that form 28 parent trio sets and 27 sibling trio sets. The remaining 1085 samples were taken from controls. In line
with previous findings, where MND has been diagnosed, the breakdown of gender in the collection is around 60 % male (a). The average age of
onset was approximately 62 years of age (c). In total 2653 frozen lymphoblastoid cell lines are held in storage at ECACC. Of these 1267 samples
were generated from whole blood taken from patients with sporadic MND. 115 cell lines were generated from familial samples and the
remaining 1058 cells lines have been established using blood samples obtained from control or family members (d)
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[19]. Researchers would need to directly compare gen-
omic DNA from the central nervous system with that
from the UK MND DNA Bank to completely resolve
this issue. Similarly, researchers who request access to
transformed cell lines for use in genomic based research
are also advised to carefully validate cell lines both at the
start and end of their project using robust techniques
such as STR profiling. Transformed cell lines may have
genetic changes and rearrangements, and cell lines them-
selves can show genetic instability and phenotypic drift
through prolonged culture. Cell line authentication is
in accordance with the guidelines published by the Inter-
national Cell Line Authentication Committee (ICLAC)
[20] and is well documented as part of the terms and
conditions of sample use.
Obtaining high quality clinical data also presents a
problem for the DNA Bank. The extended dataset for
the collection is extremely valuable but is incomplete.
Clinical information is dynamic and changes over time.
Whilst it is possible to access patient records and update
the dataset for some fields, such as to record the date
of death of a patient to provide information about
survival, or to update results from gene screens, this is
not possible for all fields within the database and can
be a complicated process. Having a clearly defined mi-
nimum dataset from the beginning helps manage this
constraint, but deciding what parameters should be
included in the minimum dataset is difficult; the pertin-
ent data of the future may not be the same as today and
as a result some enquiries from researchers will always
end in frustration.
As part of the governance of the DNA Bank, the
MND Association must ensure compliance with legal
and regulatory requirements. The Association must also
guarantee that the resource adheres to rigorous research
standards and is used in the further understanding of
motor neuron disease; this includes prioritising access
to those parts of the DNA Bank that are limited in
availability, clarifying intellectual property rights and
disseminating the results that flow from it.
To date more than twenty projects have withdrawn
samples from the DNA Bank. DNA samples have been
used in complex, technical protocols such as genotyping,
gene sequencing and genome-wide association studies
and numerous papers have been published or are in
press [21–32]. Importantly, projects using samples from
the DNA Bank have directly led to the detection of
several MND causing genes including C9orf72 and more
recently Tub4A [21, 23, 28, 29, 32]. With researchers
now encouraged to publish in an open access format as
part of the DNA Bank governance, and to deposit data
Fig. 2 Clinical information available from the UK MND DNA Bank
Table 2 Quality control PCR assay fail rate
Type of assay No. samples screened % assay fail
Abi Identifier Kit - AMEL Marker 768 1.30
Gender based PCR - AMEL marker 2750 0.62
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from sequencing projects within accessible databases
such as ALSOD: the Amyotrophic Lateral Sclerosis
Online Database [7] and European Genome-Phenome
archive [33], the dissemination and discussion of results
by the research community is ensured. In 2014 a pro-
posal to perform whole genome sequencing on DNA
samples from the UK MND DNA Bank as part of the
international collaboration called Project MinE [34] was
approved. This exciting project will allow Next Gener-
ation Sequencing data to be collected from DNA Bank
samples and shared across research groups. The data
will also confirm the accuracy of existing studies through
imputation. It is hoped that sequencing DNA Bank
samples will allow the identification of rare variants
responsible for sporadic disease, continuously widening
our knowledge about how genetic changes can contrib-
ute to MND.
DNA Bank cell lines have also been used in a variety
of genomic projects investigating the effect of specific
gene mutations on RNA regulation and protein expres-
sion [35, 36]. This unexpected demand for the cells has
forced the DNA bank to consider the future potential of
this resource, which was originally only meant for re
stocking valuable DNA. Looking to the future, it is likely
that master and working cell banks will be created for
the most valuable cell lines in order to manage demands
on the cell lines whilst also maintaining the high stan-
dards of the collection. In addition, ethical approval to
extend the use of the cell lines beyond their original
scope of genomic research was granted in 2014 by the
Derby-East Midlands Research Ethics Committee ref no.
14/EM/1088. This change in permission will potentially
allow researchers to generate primary neuronal cultures
and highly desirable induced pluripotent stem cell (iPSC)
lines either from the current cell lines stored at ECACC,
or from the original untransformed peripheral bloody
lymphocytes [37]. The iPS cell lines could act as new
disease models for drug screening and other potential
treatments, as well as acting as tools for analysing down-
stream mechanisms involved in disease pathogenesis.
Clearly the role of the DNA Bank in the governance of
such samples will be paramount; it is simply not enough
to provide high quality samples, but following how those
samples have been used and ensuring the results are
disseminated and discussed is the only way to ensure
research continues to move forward.
The DNA Bank is the only national UK biobank
specifically created for the collection, storage and dis-
tribution of MND samples. Other biobanks have been
created for rare diseases or more specifically for neurode-
generative diseases but in all cases the number of MND
samples actually available from the biobank can be fairly
limited. Details of European biobanks and repositories
available for MND researchers are documented on the
AriSLA ALScience webpage [38]. International multicen-
tre ALS studies are beginning to bring together patients
registered in neurology clinics across countries in a bid
to work together. In 2006 the Japanese Consortium for
Amyotrophic Lateral Sclerosis (JaCALS) started recruit-
ing patients with ALS to a multicentre study. Genomic
DNA samples and B-cell lines from patients with ALS
are stored and linked to their clinical information in a
model fairly similar to the one we have followed. Clinical
research coordinators check patients’ scores on the ALS
Functional Rating Scale-revised and their prognoses
every 3 months via a telephone survey [39]. Such colla-
borations will ultimately help coordinate collections of
MND specific samples across countries and hopefully in
the future the lack of good quality MND samples may
not present the problem it once did. With large inter-
national research collaborations such as Project MinE
now more common place it is clear that having access
to such samples will be hugely important to this field
of research; for this reason alone the UK MND DNA
Bank is clearly a hugely important resource. The ori-
ginal scope of the DNA Bank was to make a quantal
difference in our understanding of MND and it is well
on the way to fulfilling this promise.
Additional file
Additional file 1: Terms and conditions for sample use from the UK
MND DNA Bank.pdf.
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